Education
About Us
Working with TipRanks
Follow Us
Nanexa AB (DE:40M)
FRANKFURT:40M
40M Stock Chart & Stats
€0.25
>-€0.01(-2.14%)
At close: 4:00 PM EST
€0.25
>-€0.01(-2.14%)
Day’s Range― - ―
52-Week Range€0.07 - €0.43
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€61.70M
Enterprise Value€635.10M
Total Cash (Recent Filing)€44.57M
Total Debt (Recent Filing)€1.12M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding164,585,050
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)6.83
Price to Sales (P/S)19.19
P/FCF Ratio-474.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€10.36M
Bulls Say, Bears Say
Bulls Say
Licensing-based Revenue ModelNanexa’s revenue model centers on partnering and out-licensing its PharmaShell platform, generating upfronts, development/regulatory milestones and royalties. This asset-light approach can scale without heavy commercial capex, enabling higher incremental margins and recurring income if partners commercialize successfully.
Conservative Balance Sheet, Low LeverageThe company’s low debt-to-equity and sizable equity base reduce financial distress risk and provide runway to fund R&D and clinical programs. This conservative capital structure supports resilience through development cycles, lowering near-term refinancing pressure and preserving strategic optionality.
Improving Operating Performance (TTM)Sharp TTM revenue acceleration combined with materially narrowed losses and a positive EBITDA demonstrates improving commercial traction and operating leverage. If sustained, this trend supports a credible path to scale, margin recovery and eventual consistent positive net income.
Bears Say
Persistent Negative Cash FlowDespite improvements, the company still generates negative operating cash flow and substantial negative free cash flow, indicating ongoing cash burn. Sustained negative cash generation requires external financing or partner milestones, elevating dilution and execution risk until cash flows stabilize.
Ongoing Unprofitability / Negative ROENet losses and a markedly negative ROE reflect that the business has yet to create shareholder value. Continued negative margins constrain reinvestment returns and heighten the need for sustained revenue growth and cost discipline to turn ROE positive over the medium term.
Revenue Lumpy And Partner-dependentReliance on partner agreements, milestone triggers and future royalties makes revenue timing and scale dependent on third-party development and commercial choices. This creates lumpy, uncertain cash flow visibility and elevates execution risk if partner programs underperform or timelines slip.
Nanexa AB News
40M FAQ
What was Nanexa AB’s price range in the past 12 months?
Nanexa AB lowest stock price was €0.07 and its highest was €0.43 in the past 12 months.
What is Nanexa AB’s market cap?
Nanexa AB’s market cap is €61.70M.
When is Nanexa AB’s upcoming earnings report date?
Nanexa AB’s upcoming earnings report date is Apr 29, 2026 which is in 53 days.
How were Nanexa AB’s earnings last quarter?
Nanexa AB released its earnings results on Feb 19, 2026. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of N/A by €0.009.
Is Nanexa AB overvalued?
According to Wall Street analysts Nanexa AB’s price is currently Overvalued.
Does Nanexa AB pay dividends?
Nanexa AB does not currently pay dividends.
What is Nanexa AB’s EPS estimate?
Nanexa AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanexa AB have?
Nanexa AB has 164,585,050 shares outstanding.
What happened to Nanexa AB’s price movement after its last earnings report?
Nanexa AB reported an EPS of €0.009 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.968%.
Which hedge fund is a major shareholder of Nanexa AB?
Currently, no hedge funds are holding shares in DE:40M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanexa AB
Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
Technical Analysis
AlzeCure Pharma AB
―
Vivesto AB
―
Klaria Pharma Holding AB
―
Enzymatica AB
―
Enorama Pharma AB
―